Literature DB >> 26701382

Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.

Hsin-Hsi Tsai1, Horng-Huei Liou1, Chih-Hsin Muo1, Cha-Ze Lee1, Ruoh-Fang Yen1, Chia-Hung Kao2.   

Abstract

OBJECTIVE: To determine whether hepatitis C virus (HCV) infection is a risk factor for developing Parkinson disease (PD).
METHODS: This nationwide population-based cohort study was based on data obtained from a dataset of the Taiwan National Health Insurance Research Database for the period 2000 to 2010. A total of 49,967 patients with viral hepatitis were included for analysis. Furthermore, 199,868 people without viral hepatitis were included for comparisons. Patients with viral hepatitis were further grouped into 3 cohorts: hepatitis B virus (HBV) infection, HCV infection, and HBV-HCV coinfection. In each cohort, we calculated the incidence of developing PD. A Cox proportional hazards model was applied to estimate the risk of developing PD in terms of hazard ratios (HRs) and 95% confidence intervals (CIs).
RESULTS: The crude HRs for developing PD was 0.66 (95% CI = 0.55-0.80) for HBV infection, 2.50 (95% CI = 2.07-3.02) for HCV infection, and 1.28 (95% CI = 0.88-1.85) for HBV-HCV coinfection. The association between HCV and PD remained statistically significant after adjustments for age, sex, and comorbidities (adjusted HR = 1.29, 95% CI = 1.06-1.56).
CONCLUSIONS: We conducted a large nationwide population-based study and found that patients with HCV exhibit a significantly increased risk of developing PD.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Year:  2015        PMID: 26701382     DOI: 10.1212/WNL.0000000000002307

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Impact of infection on risk of Parkinson's disease: a quantitative assessment of case-control and cohort studies.

Authors:  Lei Meng; Liang Shen; Hong-Fang Ji
Journal:  J Neurovirol       Date:  2019-01-10       Impact factor: 2.643

Review 2.  Can infections trigger alpha-synucleinopathies?

Authors:  Christopher T Tulisiak; Gabriela Mercado; Wouter Peelaerts; Lena Brundin; Patrik Brundin
Journal:  Prog Mol Biol Transl Sci       Date:  2019-07-03       Impact factor: 3.622

Review 3.  Evidence for association between hepatitis C virus and Parkinson's disease.

Authors:  Abdelrahman Ibrahim Abushouk; Mostafa Wanees Ahmed El-Husseny; Mayar Magdy; Ammar Ismail; Attia Attia; Hussien Ahmed; Ravikishore Pallanti; Ahmed Negida
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

4.  Infections or Sepsis Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study.

Authors:  Shemonti Hasan; Michelle M Mielke; J Eric Ahlskog; James Bower; Pierpaolo Turcano; Rodolfo Savica
Journal:  Mov Disord       Date:  2020-06-01       Impact factor: 10.338

Review 5.  Epidemiological Evidence for an Immune Component of Parkinson's Disease.

Authors:  Paulina Gonzalez-Latapi; Connie Marras
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 6.  Infections and Changes in Commensal Bacteria and the Pathogenesis of Parkinson's Disease.

Authors:  Kathleen M Shannon
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 7.  A role for viral infections in Parkinson's etiology?

Authors:  Laura K Olsen; Eilis Dowd; Declan P McKernan
Journal:  Neuronal Signal       Date:  2018-04-16

8.  Association of viral hepatitis and bipolar disorder: a nationwide population-based study.

Authors:  Lee-Won Chong; Chih-Chao Hsu; Chang-Yin Lee; Ruey-Hwang Chou; Cheng-Li Lin; Kuang-Hsi Chang; Yi-Chao Hsu
Journal:  J Transl Med       Date:  2018-06-22       Impact factor: 5.531

9.  Mitochondrial Protein PINK1 Positively Regulates RLR Signaling.

Authors:  Jun Zhou; Rui Yang; Zhaoru Zhang; Qianru Liu; Yuanyuan Zhang; Qingqing Wang; Hongbin Yuan
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

Review 10.  Epidemiology of Parkinson's Disease-East Versus West.

Authors:  Masoom M Abbas; Zheyu Xu; Louis C S Tan
Journal:  Mov Disord Clin Pract       Date:  2017-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.